EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort

Paula Olivares-Navarro iD, María Teresa Pérez-Rodríguez, Adrián Sousa, Ane Josune Goikoetxea-Agirre, María José Blanco Vidal, Antonio Plata, Eva León, Luis Buzón-Martín iD, Ángeles Pulido-Navazo, Lucía Boix-Palop, Pilar Retamar-Gentil, Carlos Armiñanzas-Castillo und 13 weitere

Journal of Antimicrobial Chemotherapy · 03.04.2026 · 81 (5)

DOI: 10.1093/jac/dkag130 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 08.04.2026. Verfasst von Paula Olivares-Navarro und 24 weiteren Autor:innen. Beteiligte Einrichtung: Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena; Departamento de Medicina, Universidad de Sevilla;…. Hauptthemen laut MEDLINE: Escherichia coli, Escherichia coli Infections, beta-Lactamases, Bacteremia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIBERINFEC, Instituto de Salud Carlos III, European Development Regional Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The incidence of bloodstream infection (BSIs) due to extended-spectrum β-lactamase (ESBL) producing Escherichia coli is increasing worldwide. There is controversy as to whether ESBL production in itself is associated with higher mortality. The aim of this study is to evaluate the impact of ESBL production on mortality in BSIs due to E. coli considering the effect of confounders.

Methods

PROBAC study is a prospective, multicentre, cohort study performed in 26 Spanish hospitals (October 2016–March 2017). All patients with E. coli BSIs were included. The outcome variable was all-cause 30-day mortality. Confounding was controlled by calculating a propensity score (PS) for ESBL production using baseline variables. PS were used as covariable, for matching, for inverse probability of treatment weight analysis and for stratified analysis within the PS quartiles.

Results

A total of 2394 cases were included, of which 322 (13.5%) were ESBL-producing isolates. The frequency of appropriate empirical treatment, in ESBL-producing and non-ESBL-producing isolates, was 53.7% and 92.0%, respectively. Thirty-day mortality was 14.6% in ESBL-producing isolates versus 9.6% in non-ESBL-producing isolates (P = 0.006), for a crude OR of 1.61 (95% CI: 1.14–2.27; P = 0.006). When we adjusted by PS and appropriate empirical treatment, the OR changed to 1.12 (95% CI: 0.75–1.67; P = 0.584). Other PS applications provided similar results.

Conclusion

BSIs due to ESBL-producing E. coli were associated with higher mortality in the crude analyses; however, the estimate of the association is reduced after adjustment for baseline variables and empirical therapy, and is not significant in matched analysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Escherichia coliEscherichia coli Infectionsbeta-LactamasesBacteremiaHumansSpainProspective StudiesAnti-Bacterial AgentsAged, 80 and over

Substanzen

beta-LactamasesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena; Departamento de Medicina, Universidad de Sevilla; Instituto de Biomedicina de Sevilla (IBiS)/CSIC, Seville, Spain.
  • CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
  • Complejo Hospitalario Universitario de Vigo, Galicia Sur Health Research Institute, Vigo, Spain.
  • Servicio de Enfermedades Infecciosas, Hospital Universitario de Cruces, Bilbao, Spain.
  • Servicio de Enfermedades Infecciosas, Hospital Regional Universitario de Málaga, IBIMA, Málaga, Spain.
  • Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen de Valme, Seville, Spain.

ORCID-Profile: Paula Olivares-Navarro, Luis Buzón-Martín, Pedro María Martínez Pérez-Crespo, Jesús Rodríguez-Baño, Luis Eduardo López-Cortés

Förderung

  • CIBERINFEC
  • Instituto de Salud Carlos III
  • European Development Regional Fund

Zitieren

APA

Olivares-Navarro, P., Pérez-Rodríguez, M. T., Sousa, A., Goikoetxea-Agirre, A. J., Blanco Vidal, M. J., Plata, A., León, E., Buzón-Martín, L., Pulido-Navazo, Á., Boix-Palop, L., Retamar-Gentil, P., Armiñanzas-Castillo, C., Fernández-Natal, I., Del Arco Jiménez, A., Jover-Sáenz, A., Fernández-Suárez, J., Martín-Aspas, A., Smithson-Amat, A., Bahamonde-Carrasco, A., …, & PROBAC/GEIRAS-SEIMC/SAMICEI (2026). Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort. Journal of Antimicrobial Chemotherapy, 81(5). https://doi.org/10.1093/jac/dkag130

Vancouver

Olivares-Navarro P, Pérez-Rodríguez MT, Sousa A, Goikoetxea-Agirre AJ, Blanco Vidal MJ, Plata A, et al. Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort. Journal of Antimicrobial Chemotherapy. 2026;81(5). doi:10.1093/jac/dkag130

BibTeX
@article{OlivaresNavarro2026,
  author = {Olivares-Navarro, Paula and Pérez-Rodríguez, María Teresa and Sousa, Adrián and Goikoetxea-Agirre, Ane Josune and Blanco Vidal, María José and Plata, Antonio and León, Eva and Buzón-Martín, Luis and Pulido-Navazo, Ángeles and Boix-Palop, Lucía and Retamar-Gentil, Pilar and Armiñanzas-Castillo, Carlos and Fernández-Natal, Isabel and Del Arco Jiménez, Alfonso and Jover-Sáenz, Alfredo and Fernández-Suárez, Jonathan and Martín-Aspas, Andrés and Smithson-Amat, Alejandro and Bahamonde-Carrasco, Alberto and Natera-Kindelán, Clara and Martínez Pérez-Crespo, Pedro María and López-Hernández, Inmaculada and Rodríguez-Baño, Jesús and López-Cortés, Luis Eduardo and PROBAC/GEIRAS-SEIMC/SAMICEI, PROBAC/GEIRAS-SEIMC/SAMICEI},
  title = {Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {5},
  doi = {10.1093/jac/dkag130}
}
Kostenlos starten →